Literature DB >> 7224715

Biphasic actions of chlorpromazine and mepacrine on modulation of hepatic cell injury in the perfused cat liver.

H Araki, R C Peck, A M Lefer.   

Abstract

The effect of chlorpromazine (CPZ) and mepacrine on hypoxic liver cell damage was studied using an isolated perfused cat liver preparation. High concentrations of CPZ (10(-4) M) significantly augmented the hypoxic leakage of the lysosomal enzyme, cathepsin D, and the cytoplasmic enzyme, lactate dehydrogenase (LDH) into the perfusate. The per cent free cathepsin D activity of hepatic tissue was significantly higher in the 10(-4) M CPZ treated groups (87%) than in the vehicle group (65%). CPZ at a concentration of 10(-6) M also possessed a detrimental effect on hypoxic liver integrity but to a lesser extent compared to 10(-4) M. In contrast, low concentrations of CPZ (10(-7) M) showed a protective effect during hypoxia (i.e., significantly lower perfusate cathepsin D activity and per cent free cathepsin D activity) compared to livers receiving only the vehicle. Mepacrine, another phospholipase A2 inhibitor, showed no significant effect on hypoxic liver damage at concentration of 10(-6) and 5 x 10(-5) M. CPZ has a biphasic action on liver integrity during hypoxia, low concentrations being protective and high concentrations are deleterious. Mepacrine had no significant effect in the hypoxic liver.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7224715

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  2 in total

1.  Protective effect of nifedipine in the hypoxic perfused cat liver.

Authors:  R C Peck; A M Lefer
Journal:  Agents Actions       Date:  1981-07

2.  Chlorpromazine-induced perturbations of bile acids and free fatty acids in cholestatic liver injury prevented by the Chinese herbal compound Yin-Chen-Hao-Tang.

Authors:  Qiaoling Yang; Fan Yang; Xiaowen Tang; Lili Ding; Ying Xu; Yinhua Xiong; Zhengtao Wang; Li Yang
Journal:  BMC Complement Altern Med       Date:  2015-04-16       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.